Product Images Xigduo XR

This appears to be a graph or chart related to the drug Dapagliflozin. It is showing the percentage of patients with an event over a period of time. However, without more context it is difficult to determine the exact nature of the events being measured. The graph displays the number of patients at risk for Dapagliflozin and a placebo at different increments of time.*

This is a clinical trial data table comparing the use of Dapagliflozin to placebo in a group of patients. The numbers show the number of patients who had an event (%), the hazard ratio (HR) and 95% confidence intervals, as well as the number of patients at risk in each group over a 24-month period. The table is not enough to determine what the event was and what it means.*

This appears to be a graph displaying the results of a study comparing the effects of Dapagliflozin versus Placebo over a period of 32 months. The graph shows that Dapagliflozin has a lower hazard ratio than Placebo. It also shows the number of patients at risk at different time points during the study.*

This is a graph showing the correlation between CFB (change from baseline) in 24-hour urinary glucose levels and different doses of Dapagliflozin (mg) in both healthy subjects and subjects with T20M. The graph includes observed values and fitted lines for both groups.*

The text describes graphs showing the adjusted mean change from baseline HbA1c levels at week 24 for randomized subjects who completed a study either with Dapagliflozin 10 mg + Metformin XR, Dapagliflozin 10mg, or Metformin XR. The left side graph displays values for adjusted mean change from baseline based on a longitudinal repeated measures model. The right side graph shows values for adjusted mean change from baseline and 95% Cls based on an ANCOVA model. Both graphs include randomized subjects who had baseline and at least one post baseline HbA1c value before requiring a rescue.*

Xigduo XR is a medication used to treat type 2 diabetes. It comes in the form of extended-release tablets and should be swallowed whole. The medication guide should be dispensed with the tablets. AstraZeneca is the manufacturer of Xigduo XR.*

Xigduo XR is a medication available in the form of 30 extended-release tablets. It is a combination of dapagliflozin and metformin hydrochloride, with a strength of 5mg/500mg. The tablets should not be crushed, cut, or chewed, and must be swallowed whole. A Medication Guide accompanies the tablets during dispensation. The National Drug Code (NDC) for this medicine is Bi0:6250:30. This medication is Rx-only, and XIGDUO is a trademark of the AstraZeneca group of companies. This text seems to be a label or package insert for Xigduo XR tablets with warnings and instructions for use.*

Xigduo XR is a brand name of tablets containing dapagliflozin/metformin HCI. These extended-release tablets are available in a strength of 10mg/500mg and must be swallowed whole. Crushing, cutting, or chewing the tablets is not recommended. Dispensing with a medication guide is also suggested. Xigduo XR is a trademark of the AstraZeneca group.*

This is a description of a medication called Xigduo XR, available in tablet form with a strength of 10 mg/1000 mg. The medication is made by AstraZeneca and comes in a bottle of 130 tablets. It is an extended-release medication that should not be crushed, cut, or chewed and should be swallowed whole. The medication guide should be dispensed with the tablets.*